Analyst Upgrades: Amazon.com, Inc., ZS Pharma Inc, and Oracle Corporation

Analysts upwardly revised their ratings and price targets on Amazon.com, Inc. (NASDAQ:AMZN), ZS Pharma Inc (NASDAQ:ZSPH), and Oracle Corporation (NYSE:ORCL)

Sep 11, 2015 at 9:10 AM
facebook twitter linkedin


Analysts are weighing in on e-tailer Amazon.com, Inc. (NASDAQ:AMZN), biotech ZS Pharma Inc (NASDAQ:ZSPH)and software giant Oracle Corporation (NYSE:ORCL). Here's a quick roundup of today's bullish brokerage notes on AMZN, ZSPH, and ORCL.

  • AMZN is pointed slightly lower ahead of the open, even after RBC raised its price target to $705 from $650 -- record-high waters. This bullish attention reflects the general opinion on the Street, where 23 of 29 brokerage firms call Amazon.com, Inc. a "buy" or better. However, even though the shares have added over 68% this year to trade at $522.24, bearish betting has been popular in the options pits. AMZN's 10-day International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) put/call volume ratio of 1.11 is only 2 percentage points from an annual high. 

  • ZSPH added over 28% yesterday, touching an all-time high of $84.85 before closing at $74.73, on news the company is in M&A talks with fellow drugmaker Actelion Ltd. This momentum appears ready to carry over into today, with the shares positioned 5.7% higher in electronic trading. Providing an extra boost is a price-target hike to $110 at William Blair, which would mark an all-time high for ZS Pharma Inc. Considering ZSPH's recent technical performance, though, nothing is out of the question -- the shares have surged 89.6% in the past 12 months. 

  • It hasn't been a great time for ORCL shareholders, with the security lagging the S&P 500 Index (SPX) by nearly 10 percentage points during the past three months, last seen a $37.61. Additionally, the shares have struggled against their 20-day trendline over this same time frame. However, BTIG started ORCL with a "buy" rating this morning, although the bullish attention has done little to move the pre-market needle. This lackluster price action will most likely be well-received in the options pits, considering ORCL's 10-day put/call volume ratio at the ISE, CBOE, and PHLX stands at an annual high of 4.37. In other words, puts have been bought to open over calls at an annual-high clip.

Get the skinny on all the biggest stories of the morning… Sign up now to get Schaeffer's Midday Market Check delivered straight to your inbox!

 

If you are not making money with options, you aren’t buying options like this…

There is no options strategy that more perfectly approaches trading the fastest moving and most volatile stocks available in the marketplace than this one. In fact, there is no strategy that better utilizes put options for optimal returns and a real trading edge over other traders in the exact same market. New options traders fail out at an incredible rate without proper trade research, execution timing, and option picking. Capitalize on Schaeffer’s 100+ years of options trading excellence with the most coveted product launch in company history. Don't waste another second... join us right now before the next round of trades are released!

SCHAEFFER'S JULY STOCKS REPORT AD
 


 


 
Special Offers from Schaeffer's Trading Partners